Mark Jones, PhD

Basilea Pharmaceutica International Ltd
Allschwil, Basel-Landschaft, Switzerland

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB2302 - Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)

  Saturday, October 22, 2022
  1:45 PM – 1:57 PM US ET